The role of genomics in oncology

Share :
Published: 28 Oct 2014
Views: 2831
Rating:
Save
Dr Carlos Felipe M. de Araujo – Fiocruz Research Center - Rio de Janeiro, Brazil

Dr Felipe talks to ecancertv about the role of molecular biology and genomic sequencing in personalising cancer care. In particular, he stresses the importance of reassuring doctors that this is not something that is beyond their grasp either financially or intellectually.

VIII Franco Brazilian Congress of Oncology

The role of genomics in oncology

Dr Carlos Felipe M. de Araujo – Fiocruz Research Center - Rio de Janeiro, Brazil


I’m for molecular oncology and it’s a very interesting initiative from Dr José Claudio Casali and it’s amazing because it brings specialists of molecular biology and try to share this knowledge with the physicians to inspire them to use this knowledge up-front, this molecular biology knowledge, in the treatment and diagnosis. My part specifically is in the final of the lecture, we make a practical lecture and we invite the participants to make a DNA extraction from strawberry, that’s a very simple extraction and they can do it also at home, and we try to bring them to the lab and make them feel this, how it is to work in the lab. We also make a [?? 1:23] experimentation, very simple also, but we can try to make them lose this fear of molecular biology and stimulate them to apply this in the diagnosis and in the treatment of cancer.

My part is very simple, it’s something, we really try to make them use the different kinds of diagnosis tumour then to sequence some genes that can make a personal diagnostic, a diagnosis directed from each person. Because each people are different and with the molecular biology we can direct the treatment specifically for each person, so that’s the most important. So some people, some physicians, are afraid to use these techniques so this course is very important because we are trying to convince them that it’s not anything; it isn’t anything problematic or very expensive or something from the moon or a spaceship, not of this. It’s very simple, they can do it, it’s not so expensive. Actually, some kinds of diagnosis are something about, I don’t know, 4-5 Reals, it’s not expensive or something, we can do this with no problem.

So we also discuss the [?? 3:07] with the treatment and discuss some different techniques that we can use and just try to show them that it’s not something very complicated, it’s very easy to understand it. We just try to encourage them to use these resources.

In Franco Brazilian, in this congress, we are in the fourth time and it’s very good. We make people laugh and we stand up and they can do the extraction with their hands and that’s very cool. They can feel how to work with DNA, they can touch the DNA, so that’s amazing. That’s very good.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )
25 Mar 2024

Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023

2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab

Dr Sapna Patel - MD Anderson Cancer Center, Houston, USA
2 year recurrence free survival benefit for resectable melanoma treated with neoadjuvant/adjuvant pembrolizumab ( Dr Sapna Patel -  MD Anderson Cancer Center, Houston, USA )
2 Nov 2023

Epitope editing enables targeted immunotherapy of acute myeloid leukaemia

Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA
Epitope editing enables targeted immunotherapy of acute myeloid leukaemia ( Dr Gabriele Casirati - Dana-Farber Cancer Institute, Boston, USA )
3 Oct 2023

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023

Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma

Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain
Selinexor, bortezomib and dexamethasone shows PFS benefit for multiple myeloma ( Dr Maria-Victoria Mateos - University Hospital Salamanca, Salamanca, Spain )
19 Jun 2023

ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy

Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA
ADCLEC.syn1 and CD33-CARS in humanised acute myeloid leukaemia models shows promising efficacy ( Dr Sascha Haubner - Memorial Sloan Kettering Cancer Center, New York City, USA )
19 Jun 2023

Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens

Dr Krina Patel - MD Anderson Cancer Center, Houston, USA
Ide-cel significantly prolongs PFS for r/r multiple myeloma versus standard regimens ( Dr Krina Patel - MD Anderson Cancer Center, Houston, USA )
19 Jun 2023

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )
15 Jun 2023